Zenas BioPharma, Inc.ZBIO

Zenas BioPharma is a clinical-stage biotech that wants you to believe its obexelimab pipeline is the next big thing in autoimmune disease. The trouble is, the only thing currently large is the gap between the company’s valuation narrative and its $10.0 million quarterly revenue. The firm’s income statement for the 12 months to March 31 2026 shows $10.0 million in sales, $81.0 million in net losses, and a $75.2 million cash burn from operations. Translation: the company is spending like a late-stage startup while acting like an early-stage one. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1953926/000119312526274473/xslF345X06/ownership.xml)

What Zenas actually does is run clinical trials for obexelimab, an antibody program aimed at autoimmune diseases. The company’s own pages promise transformative therapies and patient-first commitments, but the balance sheet remains stubbornly untransformed. Assets of $747.7 million look impressive until you subtract $411.9 million in liabilities, leaving equity of $335.8 million. Cash and short-term investments total $717.2 million, which is cold comfort when you’re burning $75 million a year and have no marketed product. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1953926/000119312526274473/xslF345X06/ownership.xml; Clinical Trials - Zenas BioPharma, https://zenasbio.com/patients-caregivers/clinical-trials/)

Quarterly results show operating losses of $77.3 million and a diluted loss per share of $1.46 on 55.6 million shares outstanding. Research and development expense clocked in at $60.4 million for the period, which is where the real work-and the real cash outflow-is happening. Capex was a negligible $2,000, so the company isn’t even spending on bricks and mortar. The only thing growing is the trial roster and the burn rate. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1953926/000119312526274473/xslF345X06/ownership.xml; Pipeline - Zenas BioPharma, https://zenasbio.com/our-science/pipeline/)

The company’s SEC filings read like a corporate time capsule: a February 2026 collaboration letter with InnoCare Pharma carved up IL-17 territory rights, and a March 2026 amendment tweaked a revenue-participation side deal from September 2025. Neither document produced revenue, and neither changed the cash-burn math. The filings are thorough, but the business impact is invisible. If you want to see the latest submissions matrix, the SEC’s JSON feed is here: https://data.sec.gov/submissions/CIK0001953926.json. (source: SEC submissions JSON, https://data.sec.gov/submissions/CIK0001953926.json; First Amendment to the Revenue Participation Right Purchase and Sale Agreement, https://www.sec.gov/Archives/edgar/data/1953926/000110465926059735/zbio-20260331xex10d4.htm)

For context on the clinical pipeline, Zenas lists multiple global trials for obexelimab on its patient site, but none have yet delivered a pivotal readout capable of moving the needle on revenue. The company’s commitment page promises that trials are designed to generate safety and efficacy data, which is biotech for ‘trust us, the data will be fine.’ Until then, the stock is a bet on regulatory faith rather than product sales. The trial roster is here: https://zenasbio.com/patients-caregivers/clinical-trials/. (source: Clinical Trials - Zenas BioPharma, https://zenasbio.com/patients-caregivers/clinical-trials/; Our Commitment - Zenas BioPharma, https://zenasbio.com/patients-caregivers/)